SLC5A2 and diabetes mellitus: This demonstration of the cardiovascular benefits of an SGLT2 inhibitor in patients without diabetes provides support for prior suggestions that such treatment has beneficial actions other than glucose lowering and extends the therapeutic role of dapagliflozin beyond patients with diabetes.